- Home
- RPRX vs CELH Comparison
RPRX vs CELH Comparison
Compare RPRX & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- CELH
- Stock Information
- Founded
- RPRX 1996
- CELH 2004
- Country
- RPRX United States
- CELH United States
- Employees
- RPRX N/A
- CELH N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- CELH Beverages (Production/Distribution)
- Sector
- RPRX Health Care
- CELH Consumer Staples
- Exchange
- RPRX Nasdaq
- CELH Nasdaq
- Market Cap
- RPRX 16.2B
- CELH 15.3B
- IPO Year
- RPRX 2020
- CELH N/A
- Fundamental
- Price
- RPRX $40.42
- CELH $59.92
- Analyst Decision
- RPRX Strong Buy
- CELH Strong Buy
- Analyst Count
- RPRX 3
- CELH 18
- Target Price
- RPRX $46.00
- CELH $64.06
- AVG Volume (30 Days)
- RPRX 2.8M
- CELH 3.8M
- Earning Date
- RPRX 11-05-2025
- CELH 11-06-2025
- Dividend Yield
- RPRX 2.18%
- CELH N/A
- EPS Growth
- RPRX N/A
- CELH N/A
- EPS
- RPRX 1.77
- CELH 0.39
- Revenue
- RPRX $2,349,553,000.00
- CELH $1,666,480,000.00
- Revenue This Year
- RPRX $36.16
- CELH $85.38
- Revenue Next Year
- RPRX $2.04
- CELH $31.08
- P/E Ratio
- RPRX $22.85
- CELH $151.82
- Revenue Growth
- RPRX 3.69
- CELH 11.85
- 52 Week Low
- RPRX $24.05
- CELH $21.10
- 52 Week High
- RPRX $41.00
- CELH $66.74
- Technical
- Relative Strength Index (RSI)
- RPRX 74.39
- CELH 47.80
- Support Level
- RPRX $35.92
- CELH $56.96
- Resistance Level
- RPRX $37.40
- CELH $62.55
- Average True Range (ATR)
- RPRX 1.09
- CELH 2.10
- MACD
- RPRX 0.26
- CELH -0.62
- Stochastic Oscillator
- RPRX 91.94
- CELH 32.74
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.